Download presentation
Presentation is loading. Please wait.
Published byAntoon Visser Modified over 6 years ago
1
Exome Sequencing Extends the Phenotypic Spectrum for ABHD12 Mutations
Koji M. Nishiguchi, PhD, MD, Almudena Avila-Fernandez, PhD, Ramon A.C. van Huet, MD, Marta Corton, PhD, Raquel Pérez-Carro, MSc, Esther Martín-Garrido, MSc, María Isabel López-Molina, MD, Fiona Blanco-Kelly, MD, PhD, Lies H. Hoefsloot, PhD, Wendy A. van Zelst-Stams, MD, PhD, Pedro J. García-Ruiz, MD, Javier del Val, MD, Silvio Alessandro Di Gioia, PhD, B. Jeroen Klevering, MD, PhD, Bart P.C. van de Warrenburg, MD, PhD, Carlos Vazquez, MD, Frans P.M. Cremers, PhD, Blanca García-Sandoval, MD, PhD, Carel B. Hoyng, MD, PhD, Rob W.J. Collin, PhD, Carlo Rivolta, PhD, Carmen Ayuso, MD, PhD Ophthalmology Volume 121, Issue 8, Pages (August 2014) DOI: /j.ophtha Copyright © 2014 American Academy of Ophthalmology Terms and Conditions
2
Figure 1 A, Pedigrees of the 3 studied families with ABHD12 mutations. The index case is indicated with an arrow. Sanger sequencing confirmed the mutations identified by whole exome sequencing (WES) and revealed their complete cosegregation with the disease. The chromatograms of a mutant and a control individual are depicted for each variant (arrows). B, Cross-species comparison of 3 regions of ABHD12 indicates that the 3 identified missense mutations affect highly conserved residues. C, Three-dimensional structural model of ABHD12. The Ile amino acid residue at position 202 (purple) may lead to distortion of the active site (yellow) of the other monomer. For variant p.His372Gln, the Gln amino acid residue at position 372 (red) does not seem to impair the predicted structure of the protein. The His residue is shown in orange. For variant p.Arg186Pro, the change, Arg (green) to Pro (red), seems to disturb the predicted structure of the protein. The hydrogen bonds and hydrophobic interactions are shown in yellow. D, Intron–exon structure of ABHD12 and location of all mutations identified so far. Mutations previously associated with polyneuropathy, hearing loss, cerebellar ataxia, retinitis pigmentosa, and early-onset cataract (PHARC) syndrome or PHARC-like syndrome are shown in black. Red exons indicate the α-β hydrolyze domain of the protein. The mutations identified in this study and associated with PHARC syndrome or nonsyndromic retinitis pigmentosa are shown in red. Ophthalmology , DOI: ( /j.ophtha ) Copyright © 2014 American Academy of Ophthalmology Terms and Conditions
3
Figure 2 Phenotype of patients from the RP-1292 and W families with mutations in the ABHD12 gene. A, Spectrum of fundus findings in different individuals. Funduscopy of 3 patients of the RP-1292 family (II:4, II:5, and II:7) shows pale optic discs, attenuation of retinal vessels, and bone spicule pigmentation. Funduscopy of patient II:1 of the W family shows pallor of the optic disc, attenuation of the arterioles, and parafoveal atrophy with bull's-eye appearance B, Pure-tone air conduction audiograms of the patients. The grey areas are the hearing ranges for normal individual at 70 to 79 years of age (women), 70 to 79 years of age (men), and 60 to 69 years of age (men), respectively, as reported by Cruickshanks et al.32 Family RP-1292: for patients II:4 (female) and II:7 (male), the audiogram shows age-related hearing loss. Audiogram of the patient II:5 (male) shows hearing loss of the right ear. Family W : audiogram of the patient II:1 shows sensorineural hearing loss of both eyes. C, Magnetic resonance imaging (MRI) scans. Family RP-1292: for patient II:4, MRI scan shows minimal cerebral atrophy (white arrow), whereas in patient II:5, some injuries in the left cerebellum hemisphere consistent with the consequence of an ischemic event (white arrow) are present. Patient II:7 has a minimal abnormality probably resulting from an ischemic injury (white arrow). Family W : for patient II:1, no structural abnormalities of the cerebellum are observed. Ophthalmology , DOI: ( /j.ophtha ) Copyright © 2014 American Academy of Ophthalmology Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.